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Abstract
Parkinsonism is a movement disorder characterized by several cardinal motor
symptoms: resting tremor, akinesia, bradykinesia, rigidity, and postural instability.
Parkinsonian resting tremor can be modeled in rodents using the tremulous jaw
movement model. Tremulous jaw movements (TJMs) are defined as “rapid vertical
deflections of the lower jaw that resemble chewing but are not directed at any particular
stimulus.” TJMs occur in a frequency range of 3-7 Hz and are induced by a number of
pharmacological manipulations that parallel those seen in human Parkinsonism including
dopamine (DA) depleting agents, DA antagonists, and cholinomimetic administration.
Additionally, TJMs can be attenuated using antiparkinsonian agents including L-DOPA,
DA agonists, anticholinergics, and adenosine A2A antagonists. Tetrabenazine (TBZ) is a
reversible VMAT2 inhibitor that is approved by the FDA for treatment of chorea
associated with Huntington’s disease (HD). While TBZ inhibits storage of all
monoamines into synaptic vesicles it has been shown to preferentially target DA.
Therefore, patients being treated with TBZ often experience depression and Parkinsonism
as side effects. The present studies demonstrate the ability of TBZ to induce Parkinsonian
tremor using the tremulous jaw movement model. When administered to rats,
tetrabenazine (0.25, 0.5, 1.0, 2.0 mg/kg IP) significantly induces tremulous jaw
movements in a dose-dependent manner. Freeze frame video analysis reveals these TJMs
primarily occur in the 3.0-7.5 Hz frequency range, which falls in the frequency range
characteristic of parkinsonian resting tremor. Coadministration of the adenosine A2A
antagonist MSX-3 (1.25, 2.5, 5.0, 10.0 mg/kg IP) significantly attenuates TJMs induced
by 2.0 mg/kg TBZ in rats. Similarly, coadministration of MSX-3 (2.5, 5.0, 10.0 mg/kg
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IP) significantly reduces the number of TJMs induced by 10.0 mg/kg TBZ in mice. To
provide a cellular marker of these pharmacological conditions, we examined c-Fos
expression in the ventrolateral neostriatum (VLS), the region of the brain most closely
associated with the production of TJMs. 2.0 mg/kg TBZ significantly increased the
number of c-Fos positive cells in the VLS, while coadministration of 10.0 mg/kg MSX-3
significantly reduced the number of c-Fos positive cells. Taken together, the results
indicate that TBZ induces tremor as measured in the tremulous jaw movement model.
MSX-3 is capable of attenuating this behavior by blunting the cellular effects caused by
TBZ administration, thus lending further support to the use of adenosine A2A antagonists
as antiparkinsonian agents.

Chapter 1: General Introduction
Parkinson’s Disease and Parkinsonism
Parkinson’s Disease (PD) currently affects between 1 and 2 million people in the
United States (Ostrem et al., 2010). With several million cases worldwide, it is the second
most common neurodegenerative disorder, after Alzheimer’s disease (Nussbaum et al.,
2003). Age is considered the strongest risk factor for PD, as it affects 1-2% of the
population older than 65 years, and over 3% of the population older than 85 years. Given
the current aging of the population, the prevalence of PD is expected to increase
dramatically over the next decade (Ostrem et al., 2010; Shulman et al., 2011). PD is
usually diagnosed between ages 70 and 80 and progresses chronically and slowly until
death, on average 15 years after initial diagnosis (Shulman et al., 2011). Upon
postmortem examination of brains of PD patients, researchers have identified the
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presence of Lewy bodies (ubiquinated protein deposits in the cytoplasm) and Lewy
neurites (proteinaceous inclusions within neurites), both of which contain aggregates of
the protein α-synuclein (Nussbaum 2003). However, the neuropathological hallmark of
PD is the death of dopamine (DA) producing cell bodies in the substantia nigra pars
compacta, which causes the degeneration of nigrostriatal DA neurons (Hornykiwicz,
1973). In idiopathic PD, this decrease in nigrostriatal input leads to a net increase in
inhibitory output from the globus pallidus interna (i.e., medial globus pallidus) and the
substantia nigra pars reticulata, ultimately affecting the function of the motor cortex and
brainstem motor areas.
Idiopathic PD, however, is just one member of a broader family of movement
disorders known as Parkinsonism. In addition to PD, Parkinsonism includes encephalitic,
pugilistic, and drug-induced Parkinsonism. Drug-induced Parkinsonism is the second
most common cause of Parkinsonism (Alvarez et al. 2007); it can result from
administration of pharmacological agents that interfere with DA transmission such as DA
antagonists (e.g. haloperidol or pimozide) and DA depleting agents (e.g. reserpine)
(Marsden et al., 1975; McEvoy, 1983; Arbaizar et al., 2008). Additionally, several
clinical studies have shown that cholinomimetic administration can induce or exacerbate
Parkinsonian motor symptoms, including tremor, in humans (Iwasaki et al. 1988; Ott and
Lannon, 1992; Kao et al., 1993; Keltner, 1994; Aarsland et al. 2003) Parkinsonism is
characterized by several cardinal motor symptoms: resting tremor (3-7 Hz), bradykinesia
(slowed movement), akinesia (lack of initiation of spontaneous movement), rigidity
(increased muscular tone), and postural instability (Marsden et al., 1975; Findley, 1988;
Bergman et al,. 2002, Ostrem et al., 2010; Shulman et al., 2011) Parkinsonian resting
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tremor, defined as a “rhythmic, oscillatory, involuntary movement,” (Ostrem et al., 2010)
is the most common hyperkinetic movement associated with parkinsonism, and occurs in
a frequency range of 3-7 Hz, which is distinct from dyskinesias (1-2 Hz), essential tremor
(8 Hz), and postural tremors (8-12 Hz) (Findley et al., 1981, Marsden, 1984; Deuschl et
al., 1996, 2000). Parkinsonian resting tremor most frequently presents unilaterally in the
distal upper extremities as a “pill rolling” movement (Ostrem et al., 2010), but usually
spreads bilaterally affecting both the upper and lower limbs, facial muscles, and the jaw,
a condition known as “rabbiting” (Weiss et al. 1980; Salamone et al., 1998; Deuschl et
al., 2000).

Tremulous Jaw Movements: An Animal Model of Parkinsonian Resting Tremor
Animal models are frequently used to gain insight into the neural circuitry
underlying human disorders, and to investigate potential treatments. Several rodent tests
are used to assess motor functions related to akinesia/bradykinesia, including locomotor
activity and catalepsy, but historically, there for many years there was little focus upon
models of tremor. Currently, the tremulous jaw movement model is the most widely used
model for studying parkinsonian tremor in rats. Tremulous jaw movements (TJMs) are
defined as “vertical deflections of the lower jaw that resemble chewing but are not
directed at any particular stimulus” (Salamone et al., 1998, 2005). In rats, the
ventrolateral neostriatum (VLS) is the critical striatal region for producing TJMs. This
area has been shown to be responsible for orofacial movements and forepaw motor
control (Salamone et al., 1990; Jicha and Salamone, 1991; Salamone et al., 1993). Local
infusion of the neurotoxin 6-hydroxydopamine (6-OHDA) into the VLS induced TJMs,
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while infusion into other striatal areas including the anteroventromedial striatum,
dorsolateral striatum, and nucleus accumbens did not (Finn et al., 1998; Jicha and
Salamone, 1991). TJMs can also be induced in rodents by administration of
pharmacological agents that reduce DA transmission, such as DA-depleting agents (e.g.
reserpine) and DA antagonists (e.g. pimozide and haloperidol) (Baskin and Salamone,
1993; Steinpreis et al., 1993; Salamone and Baskin, 1996; Correa et al., 2004; Ishiwari et
al., 2005; Salamone et al., 2008; Betz et al., 2009). While reductions in DA transmission
are strongly associated with the generation of parkinsonian tremor, acetylcholine (ACh)
has also been implicated in TJMs. Muscarinic agonists (i.e. pilocarpine, arecoline) and
anticholinesterases (i.e. tacrine, galantamine, physostigmine) increased the number of
TJMs in a dose-dependent manner (Salamone et al. 1986; Baskin et al., 1994; Mayorga et
al., 1997; Collins et al., 2010a; Collins et al., 2011). Anticholinesterases are the primary
treatment for Alzheimer’s disease, and therefore patients treated with these drugs may
also present with parkinsonian motor side effects, including tremor. Through the use of
freeze frame video analysis, researchers have been able to characterize the temporal
dynamics of TJMs. This procedure has been extensively employed, and it has been
reported that the peak local frequency of TJMs is 3-7 Hz, which corresponds to the
frequency of parkinsonian tremor in humans (Salamone et al. 1996, 1998; Finn et al.,
1997; Mayora et al., 1997; Cousins et al., 1998; Ishiwari et al., 2005; Collins et al., 2011).
EMG recordings from the temporalis muscle in rats show consistent rhythmic bursts of
EMG activity in the 3-5 Hz frequency range during bursts TJMs, again consistent with
the frequency range of Parkinsonian resting tremor (Cousins et al., 1998; Collins et al.,
2011). Furthermore, TJMs in rats can be attenuated using antiparkinsonian agents
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including L-DOPA (Cousins and Salamone, 1996; Cousins et al. 1997) DA agonists
(Baskin and Salamone, 1993; Cousins et al., 1997; Salamone et al., 2005) amantadine
(Cousins et al., 1997), muscarinic antagonists (Steinpreis et al., 1993; Cousins et al.,
1997; Mayorga et al., 1997; Betz et al., 2009) and adenosine A2A antagonists (Correa et
al. 2004; Salamone et al., 2008; Betz et al., 2009; Collins et al., 2010a, 2011, 2012;
Santerre et al., 2012). Thus, tremulous jaw movements meet a reasonable set of criteria
for use as a valid animal model of parkinsonian tremor (Salamone et al., 1998; Cenci et
al., 2002; Collins-Praino et al. 2011).
More recently, researchers have extended the TJM model to mice, thereby
providing a model for examining the effects of various genetic manipulations on
parkinsonian tremor. Similarly to rats, TJMs are induced in mice after administration of
DA-depleting agents (Lopez-Cruz et al., in prep), muscarinic agonists (Salamone et al.,
2012) and anticholinesterases (Podurgiel et al., in prep, see appendix 1), and also have
been observed to occur primarily in bursts with a peak frequency of 3-7 Hz (Salamone et
al., 2012). Recent research using this model has shown that the adenosine A2A antagonist
MSX-3 is capable of attenuating TJMs induced by the muscarinic agonist pilocarpine
(Salamone et al., 2012), and the anticholinesterase galantamine (Podurgiel et al., in prep,
see appendix 2). Furthermore, adenosine A2A receptor knockout (KO) mice show a
reduction in TJMs after administration of pilocarpine (Salamone et al., 2012) compared
to wild type (wt) controls. Thus, extending the TJM model to mice has given researchers
means to investigate a new dimension of Parkinsonism and tremorogenesis, and future
studies should continue to validate and utilize this model.
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Tetrabenazine as a Tremorogenic Agent
Tetrabenazine (TBZ) is a monoamine-depleting agent that was first introduced as
an antipsychotic drug in the 1960’s (Quinn et al., 1959). Pharmacologically, TBZ
reversibly inhibits vesicular monoamine transporter 2 (VMAT2), which is expressed in
the brain and responsible for transporting catecholamines from the cytoplasm into
synaptic vesicles. TBZ has little effect on 5-HT transport, but more selectively depletes
storage of DA and norepinephrine (NE), and has the highest binding density in DA-rich
areas of the brain including the caudate, putamen, and nucleus accumbens (Pettibone,
1984a, 1984b; Thibaut, 1995). TBZ has a high affinity for VMAT2, but not VMAT1,
which is found in the periphery as well as the brain (Fasano, 2009; Guay, 2010). In
addition to inhibiting VMAT2, TBZ blocks DA D2 receptors, but with a much lower
affinity (Reches et al., 1983). Reserpine and TBZ differ in their mechanism of action;
reserpine is an irreversible and nonselective inhibitor of both VMAT1 and VMAT2
inhibitor, while TBZ is reversible in its selective actions as an inhibitor of VMAT2.
Additionally, reserpine is more potent than TBZ, it depletes monoamine stores to a
greater extent, and has a longer recovery of monoamine stores compared to TBZ (Guay,
2010).
In May of 2008, tetrabenazine was approved by the Food and Drug
Administration (FDA) for treatment of chorea associated with Huntington’s disease (HD)
(de Tommaso et al., 2011). HD is a neurodegenerative disorder caused by an abnormally
expanded CAG region on exon 1 of the HTT gene that affects approximately 30,000
patients in the Unites States (Poon et al., 2010). HD patients display motor abnormalities,
cognitive impairments, and various degrees of psychosis (Iversen et al., 2009). Chorea
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refers to abnormal, involuntary movement and is the most common of the motor
abnormalities associated with HD (Iversen et al., 2009). Research on human HD patients
has revealed that TBZ is effective in treating chorea in both the short and long-term
(Kenney et al. 2007a, 2007b; Frank 2009; Poon et al. 2010; de Tommaso et al. 2011;
Chen et al. 2012). Frank (2009) revealed that after 80 weeks of TBZ treatment, chorea
significantly improved from baseline with a mean reduction in the total maximal chorea
(TMC) score of 4.6 units in 45 HD patients. TBZ has also been shown to be effective at
reducing chorea within hours after a single dose. Kenney et al. (2007) observed a 42.4%
average decrease in the Unified Huntington’s Disease Rating Scale (UHDRS) chorea
score in 10 HD patients who were monitored every 2 hours after TBZ administration. In
animal studies, TBZ treatment has been shown to alleviate motor deficits and reduce
striatal cell loss in the YAC128 mouse model of HD (Wang et al., 2010).
While TBZ does show promise for reducing chorea in HD patients, there are also
adverse events (AEs) associated with TBZ treatment. The most common AEs reported in
human studies include drowsiness, Parkinsonism, and depression (Kenney et al., 2007;
Frank, 2009). While Frank (2009) reported a significant average decrease in chorea after
long-term TBZ treatment, the mean parkinsonism score increased 2.1 UHDRS units in 45
patients assessed between baseline and week 80. Given the fact that TBZ depletes DA, it
is not surprising that Parkinsonism is induced. Research on Parkinsonism could therefore
utilize TBZ in animal models. More specifically, TBZ could be used as an agent for
inducing parkinsonian tremor in the jaw movement model, and provide a means for
assessing possible therapeutic treatments for Parkinsonian tremor.
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Adenosine A2A Antagonists: Treatment for Parkinson’s Disease
In recent years, researchers have examined the role of adenosine in basal ganglia
circuitry and its relevance to Parkinsonism. Adenosine is an endogenous purine
neuromodulator that has shown to be involved in the regulation of sleep, arousal,
neuroprotection, epilsepy, and the brain’s response to ethanol and opiates (Iversen et al.,
2009). Adenosine receptors are linked to g-proteins, and four subtypes are present in the
body: A1, A2A, A2B, and A3. A1 and A2A are the most common subtypes in the brain, and
have a higher affinity for adenosine than the A2B, and A3 subtypes (Ferre et al., 1997;
Iversen et al., 2009) A1 receptors are widely distributed throughout the brain, and are
linked to the g-proteins Gi/Go (Cieslak et al. 2008; Iversen et al., 2009). Therefore,
activation of A1 receptors inhibits adenylate cyclase. In the striatum, A1 receptors are
colocalized with DA D1 receptors on substance-P containing “direct pathway” medium
spiny neurons (Ferre et al., 1997, 2001; Cieslak et al., 2008). Because D1 receptors are
linked to the g-protein Gs, stimulation of these receptors induces actions on the cAMPassociated signal transduction pathway that are opposite to those produced by A1
stimulation. A2A receptors are very densely concentrated in the striatum, where they are
colocalized with DA D2 receptors on enkephalin-postive “indirect pathway” medium
spiny neurons (Fink et al., 1992; Ferre et al., 1997, 2001; Cieslak et al., 2008). These DA
D2 receptors and adenosine A2A receptors have been shown to form heterodimers (Fuxe
et al., 2003). Additionally, research has shown that these receptors converge on the same
cAMP-associated signal transduction mechanism and exert opposing effects. DA D2
receptors are linked to the g-protein Gi and inhibit adenylate cyclase, while A2A receptors
are linked to the g-proteins Gs/Golf and activate adenylate cyclase (Ferre et al., 1997;
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2001, 2008; Iversen et al., 2009). It is this interaction that has led researchers to
investigate the use of adenosine A2A antagonists as possible anti-parkinsonian agents.
There is a large body of research showing that DA and adenosine interact in an
antagonistic manner throughout the striatal complex, in both neostriatum and nucleus
accumbens. This interaction is mostly due to the selective interactions between specific
receptor subtypes, namely the D2 and A2A subtypes on enkephalin-positive neurons, and
D1 and A1 subtypes on substance P-positive neurons (Ferre et al., 1997, 2001).
Behaviorally, adenosine antagonists produce many of the same motor effects as DA
agonists, and adenosine agonists induce many of the same motor effects as DA
antagonists (Ferre et al., 2001; Font et al., 2008; Mingote et al., 2008; Randall et al.,
2011). Adenosine antagonists increase motor activities, and can be counteracted by DA
depletion or pharmacological antagonism of DA receptors (Ferre et al., 2001). Adenosine
A2A antagonists reverse behavioral deficits induced by D2 antagonists, and those induced
by D1 antagonists, albeit to a lesser degree (Hauber et al., 2001; Worden et al., 2009;
Nunes et al., 2010). Behavioral research has examined the anti-parkinsonian effects of
A2A antagonists using tests of motor function that model the cardinal motor symptoms of
Parkinsonism. Hauber et al. (1998) showed intracerebral infusion of the adenosine A2A
antagonist MSX-3 into the striatum increases locomotion and is capable of attenuating
catalepsy induced by systemic injection of the D1 antagonist SCH23390 or the D2
antagonist raclopride. Follow up research revealed that systemic administration of the
adenosine A2A antagonist CSC reversed catalepsy induced by systemic administration of
the D2 antagonist raclopride, and catalepsy induced by microinfusion of the D2
antagonist sulpiride into the striatum is attenuated by co-microinfusion of MSX-3
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(Hauber et al., 2001). MSX-3 has also been shown to reverse locomotor suppression
induced by the D1 antagonist SCH 39166, and the D2 antagonists eticlopride and
haloperidol (Ishiwari et al., 2007; Collins et al., 2010). KF17837, another A2A antagonist,
has been to attenuate catalepsy induced by haloperidol and resperine (Kanda et al., 1994),
as well as locomotor suppression and the induction of TJMs induced by haloperidol
(Correa et al., 2004). Other A2A antagonists, SCH58261 and ST1535, were found to
attenuate impairments in sensorimotor integration and initiation of movement seen in rats
with a unilateral 6-OHDA lesion (Pinna et al., 2007). A2A receptor knockout mice display
a reduction in catalepsy (Chen et al. 2001) and significantly fewer pilocarpine-induced
tremulous jaw movements (Salamone et al., 2012) compared to wild-type mice. A2A
antagonists have also been shown to attenuate TJMs induced by DA antagonists, DA
depleting agents, muscarinic agonists, and anticholinesterases (Correa et al. 2004;
Salamone et al., 2008; Betz et al., 2009; Collins et al., 2010, 2011, 2012; Santerre et al.,
2012). Salamone et al. (2008) have shown that the adenosine A2A antagonists MSX-3 and
KW6002 are capable of attenuating catalepsy, locomotion suppression, and TJMs
induced by reserpine or DA antagonism, and thus display antiparkinsonian
characteristics. In 2005, Istradefylline (KW 6002) became the first A2A antagonist to
undergo clinical trials for treatment of humans with PD, and continued research has
shown that A2A antagonism reduces PD symptoms in humans (LeWit et al., 2008).

Present Work
The present experiments sought to establish a rodent model of parkinsonian
tremor using the VMAT2 inhibitor TBZ. The first experiment examined the effect of
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various doses of TBZ on the induction of TJMs. Experiment 2 investigated the local
frequency characteristics of the TJMs induced by the peak dose of TBZ from experiment
1. This experiment was done to determine if the TJMs occur in the 3-7 Hz frequency
range, and thus could serve as a model of human Parkinsonian resting tremor and not
another form of tremor that occurs at a different frequency range. Experiments 3 and 4
evaluated the ability of the adenosine A2A antagonist MSX-3 to reverse TJMs induced by
TBZ in rats and mice. Since adenosine A2A antagonists have been shown to be
antiparkinsonian agents, it was hypothesized that MSX-3 should be able to attenuate
TBZ-induced TJMs. Finally, experiment 5 examined the ability of MSX-3 to reverse the
effects of TBZ on c-Fos in VLS, thus providing evidence at the cellular level that MSX-3
is reversing the effects of TBZ due to the convergence of D2 and A2A receptors on the cAMP associated signal transduction pathway. The VLS was chosen as the region of
interest for this study because it is the neostriatal region most closely associated with the
induction of TJM activity (Salamone et al., 1990, 1998, 2008; Jicha and Salamone 1991;
Finn et al., 1998; Collins-Praino et al., 2011), and has been used previously in studies of
c-Fos immunoreactivity associated with TJMs (Betz et al., 2009). The VLS is thought to
be the rodent homologue of the primate putamen, which is somatotopically organized in a
dorsal-ventral gradient (McGeorge and Faull, 1989). The ventral portion of the primate
putamen is responsible for orofacial movement and forelimb motor control (Alexander
and Delong, 1985), and the rodent VLS, which receives direct cortical input from head
areas of motor cortex (McGeorge and Faull, 1989), also is important for orofacial motor
function (Jicha and Salamone, 1991; Salamone et al., 1993).

12

Chapter 2: Tremulous Jaw Movements Induced by the VMAT2 Inhibitor
Tetrabenazine

2.1 Introduction
Parkinson’s Disease (PD) is the second most common neurodegenerative
disorder, after Alzheimer’s disease (Nussbaum et al., 2003). Today, 1-2 million people in
the United States suffer from idiopathic PD, which is caused by the death of dopamine
(DA) producing cell bodies in the substantia nigra pars compacta and subsequent
degeneration of nigrostriatal dopamine neurons (Ostrem et al, 2010). Idiopathic PD is just
one member of a broader family of movement disorders known as Parkinsonism, the
members of which share several cardinal motor symptoms: resting tremor, akinesia,
bradykinesia, rigidity, and postural instability. Certain classes of drugs also have been
shown to induce Parkinsonism in humans, including DA antagonists (i.e. “typical”
antipsychotics, like haloperidol and pimozide) and DA depleting agents (i.e. reserpine
and tetrabenazine) (Marsden et al., 1975; McEvoy, 1983; Arbaizar et al., 2008).
Cholinomimetics, such as the anticholinesterases used to treat Alzheimer’s disease,
induce or exacerbate Parkinsonian tremor (Iwasaki et al. 1988; Ott and Lannon, 1992;
Kao et al., 1993; Keltner, 1994; Aarsland et al., 2003).
Tetrabenazine (TBZ) is a reversible VMAT2 inhibitor approved by the FDA for
treatment of chorea associated with Huntington’s Disease (HD). TBZ depletes storage of
monoamines, but more selectively targets DA and exhibits the highest binding density in
DA-rich areas of the brain including the caudate, putamen, and nucleus accumbens
(Pettibone, 1984a, 1984b; Thibaut, 1995). Human research has indicated that TBZ is
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effective at treating HD-associated chorea in both the short and long-term, but adverse
effects (AEs) often occur (Kenney et al. 2007a, 2007b; Frank, 2009), including
drowsiness, depression, and Parkinsonism (Kenney et al. 2007a; Frank, 2009). Since it is
known that TBZ depletes DA storage and thereby reduces DA transmission, it is not
surprising that Parkinsonism results from TBZ administration. Research on Parkinsonism
could thus employ TBZ in animal models.
Parkinsonian resting tremor can be modeled in rodents using the tremulous jaw
movement model. TJMs are defined as “rapid vertical deflections of the lower jaw that
resemble chewing but are not directed at any particular stimulus” (Salamone et al. 1998).
In rodents, TJMs can be induced by the same pharmacological agents that induce
Parkinsonian resting tremor in humans, including DA depletion, DA antagonism, and
cholinomimetic administration (Baskin and Salamone, 1993; Steinpreis et al., 1993;
Baskin et al., 1994; Salamone and Baskin, 1996; Mayorga et al. 1997; Salamone et al.,
2008; Betz et al., 2009; Collins et al. 2010a, 2011). Additionally, TJMs have been shown
to occur in the 3-7 Hz frequency range, which is the same frequency range as
parkinsonian resting tremor (Salamone et al. 1996, 1998; Finn et al., 1997; Mayora et al.,
1997; Cousins et al., 1998; Ishiwari et al., 2005; Collins et al., 2011). Furthermore, TJMs
are attenuated with anti-parkinsonian drugs including L-Dopa, DA agonists, amantadine,
muscarinic antagonists, and adenosine A2A antagonists (Baskin and Salamone, 1993;
Steinpreis et al., 1993; Cousins and Salamone, 1996; Cousins et al., 1997; Mayorga et al.,
1997; Correa et al., 2004; Salamone et al., 2005, 2008; Betz et al., 2009; Collins et al.,
2010a, 2011, 2012; Santerre et al., 2012).
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Over the past few years, a large body of research has aimed at identifying the
antiparkinsonian properties of adenosine A2A antagonists. Adenosine A2A receptors are
highly concentrated in the striatal complex, including the nucleus accumbens and
neostriatum, and are colocalized with DA D2 receptors on enkephalin-positive “indirect
pathway” striatopallidal medium spiny neurons. Research has shown that these receptor
subtypes converge onto the same signal transduction pathway, and are capable of forming
heterodimers (Ferre et al., 1997, 2001; Hauber et al., 2001; Fuxe et al., 2003). Since D2
receptors are linked to the g-protein Gi, they inhibit adenylate cyclase, while adenosine
A2A receptors are linked to the g-protein Gs/Golf and activate adenylate cyclase. It is this
interaction that has lead researchers to investigate adenosine A2A antagonists as possible
antiparkinsonian agents. Animal studies have revealed that A2A antagonists are capable of
attenuating catalepsy, locomotion suppression, and also suppress the tremulous jaw
movements induced by various pro-parkinsonian agents (Kanda et al., 1994; Hauber et
al., 2001; Ishiwari et al., 2007; Pinna et al., 2007; Salamone et al., 2008; Collins et al.,
2010a). For example, the adenosine A2A antagonist KF17837 counteracted locomotor
suppression and significantly reduced tremulous jaw movements induced by the D2
antagonist haloperidol (Correa et al. 2004). In another study, KF17837 attenuated
catalepsy induced by haloperidol and the DA-depleting agent reserpine (Kanda et al.
1994). Another adenosine A2A antagonist, MSX-3, has been shown to have
antiparkinsonian properties. MSX-3 is a water-soluble phosphate prodrug that is cleaved
in vivo by phosphatases into the physiologically active compound MSX-2 (Hockemeyer
et al., 2004). MSX-3 has been shown to attenuate catalepsy, locomotion suppression, and
the induction of tremulous jaw movements induced by DA antagonism and the DA
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depleting agent reserpine (Salamone et al. 2008). Furthermore, MSX-3 significantly
reduced TJMs induced by the muscarinic agonist pilocarpine (Collins et al., 2010a;
Salamone et al., 2012), as well as the anticholinesterase galantamine (Collins et al.,
2012).
Immediate early gene (IEG) protein products, such as c-Fos, can be used to
provide a cellular marker neuronal activity. IEGs encode neural proteins involved in
signal transduction and are thought to be related to neuronal activity in the CNS (Sagar et
al., 1988). Betz et al. (2009) showed an increase in c-Fos expression in the VLS after
administration of the DA antagonist pimozide. Additionally, the A2A antagonist KW 6002
significantly attenuated pimozide-induced c-Fos expression. Recently, Santerre et al.
(2012) showed that another A2A antagonist, MSX-4, was capable of significantly reducing
c-Fos expression in the nucleus accumbens that was induced by the DA D2 antagonist
eticlopride. These studies provide further evidence that A2A antagonists blunt the cellular
actions of DA D2 antagonists by exerting opposing actions on the same c-AMP related
signal transduction pathway.
The present experiments sought to establish an animal model of parkinsonian
tremor using the VMAT2 inhibitor TBZ. Experiment 1 examined the effect of various
doses of TBZ (0.25, 0.5, 1.0, 2.0 mg/kg IP) on the induction of TJMs. Experiment 2
analyzed the frequency characteristics of the TJMs induced by the peak dose of TBZ (2.0
mg/kg) from experiment 1, to ensure that the TJMs fall into the 3-7 Hz frequency range
that is associated with human parkinsonian resting tremor. Experiment 3 investigated the
ability of the adenosine A2A antagonist MSX-3 (1.25, 2.5, 5.0, 10.0 mg/kg) to reverse
TJMs induced by the peak dose of TBZ (2.0 mg/kg) from experiment 1. Similarly, in
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experiment 4 the ability of MSX-3 (2.5, 5.0, 10.0 mg/kg) to attenuate TBZ-induced TJMs
was investigated in mice. Finally, experiment 5 sought to provide a cellular marker of
TBZ-induced TJMs by examining c-Fos expression in the ventrolateral neostriatum
(VLS) after TBZ administration (2.0 mg/kg) and with co-administration of TBZ with
MSX-3 (10.0 mg/kg). Together, this group of experiments sought to establish an animal
model of Parkinsonian resting tremor that future researchers can employ as a means for
studying the neural circuitry involved in tremorogenesis, and as a platform for evaluating
possible therapeutic agents.

2.2 Materials and Methods
Animals
A total of 38 adult male Sprague Dawley rats (Harlan Laboratories, Indianapolis,
IN) with no prior drug experience were used in the present experiments. The rats weighed
350-450g during the course of the experiment and had ad libitum access to lab chow and
water. They were pair-housed in a colony that was maintained at approximately 23°C and
had a 12-hour light/dark cycle (lights on at 0700 hrs). These studies were conducted
according to University of Connecticut and NIH guidelines for animal care and use.
A total of 10 male CD1 mice (Harlan Laboratories, Indianapolis, IN) with no
prior drug experience also were used in the present experiments. The mice weighed 35-45
g during the course of the experiment and had ad libitum access to lab chow and water.
They were group-housed in a colony that was maintained at approximately 23°C and had
a 12-hour light/dark cycle (lights on at 0700 hrs). These studies were conducted
according to University of Connecticut and NIH guidelines for animal care and use.
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Behavioral Procedures
Tremulous Jaw Movements: Rats. Observations of rats took place in a 30 × 30 × 30 cm
clear Plexiglas chamber with a wire mesh floor, which was elevated 42 cm from the table
top. This allowed for the viewing of the animal from several angles, including
underneath. Tremulous jaw movements were defined as rapid vertical deflections of the
lower jaw that resembled chewing but were not directed at any particular stimulus
(Salamone et al. 1998). Each individual deflection of the jaw was recorded using a
mechanical hand counter by a trained observer, who was blind to the experimental
condition of the rat being observed. Separate studies with two observers demonstrated an
inter-rater reliability of r = 0.98 (p < 0.001) using these methods.

Tremulous Jaw Movements: Mice. Observations of mice took place in a 11.5 × 9.5 × 7.5
cm clear glass chamber with a wire mesh floor, which was elevated 26 cm from the table
top. As with rats, tremulous jaw movements were defined as rapid vertical deflections of
the lower jaw that resembled chewing but were not directed at any particular stimulus
(Salamone et al. 1998). Each individual deflection of the jaw was recorded using a
mechanical hand counter by a trained observer, who was blind to the experimental
condition of the mouse being observed. Separate studies with two observers demonstrated
an inter-rater reliability of r = 0.98 (p < 0.001) using these methods.

Freeze Frame Analysis of Tremulous Jaw Movements: Rats were placed in a clear
Plexiglas tube (9 cm in diameter) to maintain their position so that a constant view of the
orofacial region could be seen for recording. Each rat was recorded using a (Cannon
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PowerShot SX120 digital camera, in video mode) focused on the orofacial region for
three 5-minute epochs in order to capture as many tremulous jaw movements as possible.
The sections of these video files that allowed for clear observation of the orofacial area
were then subjected to a freeze-frame analysis (1 frame = 1/30 s), in which the observer
went frame-by-frame through each burst of jaw movements (i.e. each group of at least
two jaw movements that were within 1.0 seconds of each other). The observer recorded
the inter-movement interval for each pair of jaw movements within bursts, which was
defined as the number of frames between each point at which the jaw was fully open
during successive jaw movements. This information was used to determine the local
frequency within bursts of jaw movements (i.e., the local frequency is the reciprocal of
the intermovement time).

c-FOS visualization and quantification: Free floating coronal sections (50µm) were
serially cut using a cryostat (Weymouth, MA, USA) and rinsed in 0.01M PBS (pH 7.4).
Sections were incubated in 0.3% hydrogen peroxide (H202) for 30 min to block
endogenous staining. Sections were then rinsed in PBS (3 x for 5 min) and transferred
into the primary antibody, anti- c-Fos at a concentration of 1:5000 (Calbiochem,
Germany) for 48 h incubation. Following the primary antibody treatment, sections were
rinsed in PBS (3 x for 5 min) and incubated in the secondary antibody, anti-rabbit HRP
conjugate, envision plus (DAKO, Carpinteria, CA, USA) for 2 h. The
immunohistochemical reaction was developed using diaminobenzidine (DAB) as the
chromagen. Processed sections were then mounted to gelatin-coated slides, air dried, and
cover-slipped using Cytoseal 60 (Thermo Scientific) as a mounting medium. The
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sections were examined and photographed using a Nikon Eclipse E600 (Melville, NY,
USA) upright microscope equipped with an Insight Spot digital camera (Diagnostic
Instruments, Inc). Images of the region of interest (the ventrolateral neostriatum or VLS)
were magnified at 20x and captured digitally using SPOT software. Cells that were
positively labeled for c-Fos were quantified with ImageJ software (v. 1.42, National
Institutes of Health sponsored image analysis program) and a macro written to automate
particle counting within the region of interest. The size of the region of interest counted
was 1000x1000µm. For each animal, cell counts were taken bilaterally from at least three
sections, and counts were averaged across sides and sections.

Drugs and Selection of Doses
Tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b
hexahydrobenzo[a]quinolizin-2-one), the VMAT2 inhibitor, was purchased from Tocris
Bioscience (Bristol, UK). Tetrabenazine was dissolved in a vehicle solution of 0.9%
saline (80%) and dimethyl sulfoxide (DMSO) (20%). 10 µl hydrochloric acid (HCl)/mL
volume was then added to get the drug completely into solution. MSX-3 ((E)-phosphoric
acid mono-[3-[8-[2-(3-methoxyphenyl)vinyl]-7-methyl-2,6-dioxo-1-prop-2-ynyl-1,2,6,7tetrahydropurin-3-yl]propyl] ester), the adenosine A2A antagonist, was synthesized at the
Pharmazeutisches Institut Universität Bonn; Bonn, Germany (see Hockemeyer et al.
2004). MSX-3 was dissolved in 0.9% saline. The pH of the MSX-3 solution was adjusted
by adding 1.0 N NaOH until the drug was completely in solution after conversion to its
disodium salt (pH 7.1 – 7.7).
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The doses of tetrabenazine for experiment 1 (0.25, 0.5, 1.0, and 2.0 mg/kg) were
selected based on extensive pilot work done in our laboratory. Doses higher than 2.0
mg/kg (e.g. 3.0 mg/kg, 4.0 mg/kg) induced more profound motor deficits, including
severely reduced locomotion and sedation. Therefore, we chose 2.0 mg/kg as our highest
dose for experiment 1. A dose of 2.0 mg/kg of tetrabenazine was selected for the
subsequent frequency analysis (experiment 2) and MSX-3 reversal experiment
(experiment 3) since this dose induced the maximal response and produced results that
differed significantly from the vehicle control. The doses of MSX-3 (experiment 3) (1.25,
2.5, 5.0, and 10.0 mg/kg) were selected based on previous work conduced in our
laboratory. Collins et al. (2010a) showed doses of 5.0 and 10.0 mg/kg of MSX-3 reduced
tremulous jaw movements induced by a dose of 0.5 mg/kg of the muscarinic agonist
pilocarpine. Additionally, Collins et al. (2011) found these doses (5.0 and 10.0 mg/kg
MSX-3) reduced tremulous jaw movements induced by a dose of 3.0 mg/kg of the
anticholinesterase galantamine. The dose of tetrabenazine for experiment 4 (10.0 mg/kg)
was selected based on data from López-Cruz et al. (in prep, see appendix 3), which
showed 10.0 mg/kg tetrabenazine significantly increases TJMs in CD1 mice compared to
vehicle control. The doses of MSX-3 (also experiment 4) (2.5, 5.0, 10.0 mg/kg) were
chosen based on previous data from our laboratory. Salamone et al. (2012) showed that
2.5, 5.0, and 10.0 mg/kg doses of MSX-3 significantly attenuated TJMs induced by the
muscarinic agonist pilocarpine. For experiment 5, a dose of 2.0 mg/kg tetrabenazine was
chosen based on data from experiment 1, showing this dose significantly increases TJMs
in rats compared to vehicle control. A dose of 10.0 mg/kg MSX-3 was chosen based on
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the data from experiment 3 showing this dose significantly attenuates TJMs induced by
2.0 mg/kg tetrabenazine.

Experimental Procedures
Experiment 1: Ability of tetrabenazine to induce tremulous jaw movements
A group of 10 rats was used to assess the ability of TBZ to induce tremulous jaw
movements. All rats received IP injections of either 1.0 ml/kg vehicle solution (80%
saline, 20% DMSO) or 0.25, 0.5, 1.0, or 2.0 mg/kg tetrabenazine in a within-groups
design, with all rats receiving all drug treatments in a randomly varied order (one
treatment per week; no treatment sequences repeated). One hour and 50 minutes after IP
injection, the rats were placed in the Plexiglas chamber and allowed to habituate for ten
minutes. Following the habituation period, tremulous jaw movements were counted for
fifteen minutes, with the observation period divided into three five-minute epochs.

Experiment 2: Freeze frame video analysis of local frequency of the tremulous jaw
movements induced by tetrabenazine
One week following the completion of experiment 1, 7 of the rats received an IP
injection of 2.0 mg/kg tetrabenazine. After 1 hour and 55 minutes, rats were placed in a
clear Plexiglas tube (9 cm in diameter) so that a consistent view of the orofacial area
could be achieved. After habituating for 5 minutes, each rat was recorded for 15 minutes
using a video camera. The sections of these video files that allowed for clear observation
of the orofacial area were then subjected to a freeze-frame analysis (1 frame = 1/30 s), in
which the observer went frame-by-frame through each burst of jaw movements (i.e. each
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group of at least two jaw movements that were within 1.0 seconds of each other). The
observer recorded the inter-movement interval for each pair of jaw movements within
bursts, which was defined as the number of frames between each point at which the jaw
was fully open during successive jaw movements. This information was used to
determine the local frequency within bursts of jaw movements (i.e., the local frequency is
the reciprocal of the intermovement time).

Experiment 3: The ability of the adenosine A2A antagonist MSX-3 to attenuate tremulous
jaw movements induced by tetrabenazine
A group of 10 rats were used to assess the effects of the adenosine A2A antagonist
MSX-3 on tremulous jaw movements induced by 2.0 mg/kg TBZ. A within-groups
design was utilized for this study, with all rats receiving all drug treatments in a randomly
varied order (one treatment per week; no treatment sequences repeated). On the test day
each week, each rat received an IP injection of either 1.0 ml/kg vehicle solution (80%
saline, 20% DMSO) or 2.0 mg/kg tetrabenazine. After 1 hour and 40 minutes, rats
received an IP injection of either 1.0 ml/kg saline (vehicle) or 1.25, 2.5, 5.0, or 10.0
mg/kg MSX-3. Ten minutes after injections, rats were placed in the Plexiglas observation
chamber and allowed to habituate for ten minutes. Tremulous jaw movements were then
counted for fifteen minutes, with the observation period divided into three five-minute
epochs.
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Experiment 4: The ability of the adenosine A2A antagonist MSX-3 to attenuate tremulous
jaw movements induced by tetrabenazine in CD1 mice
A group of 10 mice were used to assess the effects of the adenosine A2A
antagonist MSX-3 on tremulous jaw movements induced by 10.0 mg/kg tetrabenazine. A
within-groups design was utilized for this study, with all mice receiving all drug
treatments in a randomly varied order (one treatment per week; no treatment sequences
repeated). On the test day each week, each mouse received an IP injection of either 1.0
ml/kg vehicle solution (80% saline, 20% DMSO) or 10.0 mg/kg tetrabenazine. After 1
hour and 35 minutes, mice received an IP injection of either 1.0 ml/kg saline (vehicle) or
2.5, 5.0, or 10.0 mg/kg MSX-3. Fifteen minutes after injections, mice were placed in the
glass observation chamber and allowed to habituate for five minutes. Tremulous jaw
movements were then counted for twenty minutes, with the observation period divided
into four five-minute epochs.

Experiment 5: Ability of MSX-3 to reverse the effects of tetrabenazine on c-Fos
immunoreactivity in ventrolateral neostriatum
Experimentally naïve rats (n=18; 6 per group) were randomly assigned to the
following IP treatments: 80% saline, 20% DMSO vehicle plus saline vehicle, 2.0 mg/kg
tetrabenazine plus saline vehicle, or 2.0 mg/kg tetrabenazine plus 10.0 mg/kg MSX-3.
Rats received an injection of 1.0 ml/kg vehicle solution (80% saline, 20% DMSO) or 2.0
mg/kg tetrabenazine. 1 hour and 10 minutes later, rats received an injection of 1.0 ml/kg
saline (vehicle) or 10.0 mg/kg MSX-3. After twenty minutes, animals were anesthetized
with CO2 and perfused with physiological saline followed by 3.7% formaldehyde; brains
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were removed and stored at 4 °C in formaldehyde for one day, and then were put in 0.9%
sucrose.

Data Analysis
The data for experiments 1-4 were analyzed using a repeated measures analysis of
variance (ANOVA). The data for experiment 5 were analyzed using between-groups
ANOVA. A computerized statistical program (SPSS 14.0 for Windows) was used to
perform the analyses. For experiments 1, 3, and 4 average TJMs over the three fiveminute observation periods were calculated and then used in the ANOVA calculations.
When there was a significant ANOVA, planned comparisons using the overall error term
were used to assess the differences between each dose and the control condition; the
number of comparisons was restricted to the number of treatments minus one (Keppel,
1991). The video files from experiment 2 were analyzed using Adobe Premiere CS5.5 for
Windows, which allowed freeze-frame analysis in a frame-by-frame sequence (1 frame =
1/30 s).

2.3 Results
Experiment 1: Ability of tetrabenazine to induce tremulous jaw movements
Figure 1 shows the effect of TBZ on tremulous jaw movements. There was a
significant overall effect of tetrabenazine on TJMs (F(4,36) = 15.182; p<0.0001). The 2.0
mg/kg dose tetrabenazine significantly induced TJMs (planned comparisons, p< 0.05)
compared to vehicle control.
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Experiment 2: Freeze frame video analysis of local frequency of the tremulous jaw
movements induced by tetrabenazine
Figure 2 shows the results of the freeze frame video analysis. A total of 184 jaw
movements were analyzed. Data are shown as the number of inter-movement intervals
(i.e. the number of 1/30 s frames that elapsed from one jaw movement to another) from
jaw movement bursts, assigned to four frequency bins. To interpret these data in terms of
frequencies (i.e. jaw movements per second), the reciprocal of the inter-movement
interval was calculated (e.g. 10/30 frames per second corresponds to 3 Hz; 4/30 frames is
7.5 Hz, etc.). Repeated measures ANOVA revealed that the number of inter-movement
intervals showed an overall significant difference across the different interval bins
(F(29,174) = 14.464, p<.0001). The vast majority (92%) of the TJMs took place in the
3.0-7.5 Hz frequency range, with a peak from 4.0-6.0 Hz.

Experiment 3: The ability of the adenosine A2A antagonist MSX-3 to attenuate tremulous
jaw movements induced by tetrabenazine
Figure 3 shows the ability of the adenosine A2A antagonist MSX-3 attenuate TJMs
induced by 2.0 mg/kg TBZ. There was a significant overall effect of MSX-3 treatment on
tetrabenazine-induced TJMs (F(5,45) = 12.181; p<0.0001). 2.0 mg/kg TBZ significantly
induced TJMs compared to vehicle control (planned comparisons, p<0.05). Additionally,
all doses of MSX-3 (1.25, 2.5, 5.0, and 10.0 mg/kg) significantly reduced tetrabenazineinduced TJMs (planned comparisons, p<0.05).
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Experiment 4: The ability of the adenosine A2A antagonist MSX-3 to attenuate tremulous
jaw movements induced by tetrabenazine in CD1 mice
Figure 4 shows the ability of the adenosine A2A antagonist MSX-3 to attenuate
TJMs induced by 10.0 mg/kg tetrabenazine. There was a significant overall effect of
MSX-3 treatment on tetrabenazine-induced TJMs (F(4,36) = 9.251; p<.0001). 10.0 mg/kg
tetrabenazine significantly induced TJMs compared to vehicle control (planned
comparisons, p<.05). Additionally, all doses of MSX-3 (2.5, 5.0, and 10.0 mg/kg)
significantly reduced tetrabenazine-induced TJMs (planned comparisons, p<.05).

Experiment 5: Ability of MSX-3 to reverse the effects of tetrabenazine on c-Fos
immunoreactivity in ventrolateral striatum
The results of experiment 5 are shown in Figure 5. There was an overall effect of
drug treatment on the number of c-Fos positive cells (F (2,17) = 14.731, p < 0.0001).
TBZ increased c-Fos positive cell counts relative to vehicle alone (Tukey test, p <
0.0001), and the combination of MSX-3 plus tetrabenazine differed significantly from
tetrabenazine (Tukey test, p < 0.05), demonstrating that MSX-3 significantly reduced
TBZ-induced c-Fos expression.

2.4 Discussion
The present studies were conducted to establish an animal model of Parkinsonian
resting tremor using the VMAT2 inhibitor tetrabenazine (TBZ). By blocking vesicular
uptake, TBZ reversibly inhibits the storage of catecholamines into synaptic vesicles, and
is known to deplete DA. When administered to rats, TBZ induced TJMs in a dose-
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dependent manner. These TJMs occurred primarily in the 3-7.5 Hz frequency range, and
were attenuated with coadministration of the adenosine A2A antagonist MSX-3. MSX-3
was also capable of reducing TBZ-induced TJMs in mice. It is hypothesized that this
attenuation occurred because of the colocalization of DA D2 and adenosine A2A receptors
on enkephalin-positive “indirect-pathway” striatopallidal medium spiny neurons.
Research examining the actions of these drugs on the cellular level lends support to this
hypothesis. Administration of 2.0 mg/kg TBZ significantly increases the number of c-Fos
positive cells in the ventrolateral neostriatum (VLS) compared to vehicle control.
Additionally, coadministration of 10.0 mg/kg MSX-3 significantly reduced the number of
c-Fos positive cells.
Results from experiment 1 showed that TBZ administration increased TJMs in a
dose dependent manner, with a dose of 2.0 mg/kg significantly increasing the number of
TJMs compared to vehicle control. Pilot studies indicated that higher doses (e.g. 4.0
mg/kg) produced more severe motor impairments, akinesia, catalepsy and profound
sedation, but variable effects on TJMs. The ability of TBZ to induce TJMs is consistent
with previous studies showing another VMAT inhibitor, reserpine, also can induce TJMs
(Baskin and Salamone 1993; Salamone and Baskin 1996). Baskin and Salamone (1993)
reported that systemic administration of 2.5 mg/kg and 5.0 mg/kg of reserpine
significantly induced TJMs compared to vehicle control. In addition, DA depletions
produced by intrastriatal injections of the neurotoxic agent 6-OHDA also were shown to
induce TJMs (Jicha and Salamone, 1991; Finn et al., 1998). DA antagonists such as
haloperidol and pimozide, which are “typical” antipsychotics in humans, also have been
shown to induce TJMs (Steinpreis et al. 1993; Ishiwari et al., 2005; Salamone et al. 2008;
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Betz et al. 2009). Taken together, these results indicate that interference with striatal DA
transmission, either with DA antagonism, neurotoxic agents, or pharmacological
depletion of DA, leads to the production of TJMs in rodents. Furthermore, the ability of
TBZ to induce TJMs in rats is consistent with reports indicating that TBZ can produce
Parkinsonian symptoms in humans (Kenney et al., 2007a; Kenney et al., 2007b; Frank,
2009).
In experiment 2, a local frequency analysis of the TBZ-induced TJMs revealed
that they primarily occurred in bursts with an average frequency within bursts of 3.0-7.5
Hz, with the peak occurring between 4.0-6.0 Hz. This frequency range is consistent with
the general finding that TJMs induced by DA depletion, DA antagonism, and
cholinomimetic administration occur in the 3-7 Hz frequency range (Salamone and
Baskin 1996; Mayora et al. 1997; Cousins et al. 1998; Ishiwari et al. 2005; Collins et al.
2010; Collins et al. 2011; Salamone et al. 2012). Importantly, this frequency range is
characteristic of parkinsonian resting tremor and distinct from dyskinesias (1-2 Hz) and
postural tremor (8-12 Hz) (Findley et al. 1981; Deuschl et al. 2000). Previous research
has employed EMG methods to further characterize the local frequency of TJMs. Cousins
et al. (1998) showed that the temporalis muscle is the major contributor to the muscle
activity shown during TJMs, as indicated by consistent rhythmic bursts of EMG activity
recorded during bursts of tacrine-induced TJMs. EMG activity induced by tacrine in that
study occurred in the frequency range 3.0-5.0 Hz, again consistent with that observed in
parkinsonian resting tremor (Cousins et al., 1998). Consistent with this early report, later
research using EMG recording methods showed that bursts of TJMs induced by the
anticholinesterase galantamine were accompanied by temporalis jaw muscle activity in
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the 5.0-6.0 Hz frequency range (Collins et al., 2011). Future research should use EMG
recording methods to further characterize the local frequency of TBZ-induced TJMs.
In experiments 3 and 4, the adenosine A2A antagonist MSX-3 significantly
attenuated TBZ-induced TJMs in both rats and mice. DA D2 receptors are colocalized
with adenosine A2A receptors on enkephalin-positive “indirect pathway” medium spiny
neurons (Ferre et al., 1997, 2001, 2008) and these two receptors have been shown to form
heterodimers (Fuxe et al., 2003). DA D2 receptors are linked to the g-protein Gi, and
therefore inhibit adenylate cyclase, while adenosine A2A receptors are linked to the gproteins Gs/Golf and activate adenylate cyclase (Ferre et al., 2008). Thus, in addition to
forming heteromeric complexes, there is evidence that these receptors interact via
convergence onto the same c-AMP related signal transduction pathway, at which they
exert opposite effects (Ferre et al., 2001, 2008; Hauber et al., 2001). This opposing
interaction between receptor subtypes has led researchers to investigate adenosine A2A
antagonists as possible antiparkinsonian agents. Salamone et al. (2008) showed that
administration of MSX-3 significantly attenuated the induction of TJMs, as well as the
suppression of locomotion and the display of catalepsy, which were induced by reserpine
administration in rats. Adenosine A2A antagonists have also been shown to reverse TJMs
induced by DA antagonists and cholinomimetics (Correa et al., 2004; Salamone et al.,
2008; Betz et al., 2009; Collins et al., 2010, 2011, 2012; Santerre et al., 2012). Therefore,
results from experiment 3 are consistent with these previous studies, and lend further
support to the use of A2A antagonists as a treatment for Parkinsonian tremor.
Recently, the TJM model has been extended to mice. This is extremely valuable
given the rising importance of genetic manipulations in mice (i.e. transgenic, knockin,
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knockout). Initial studies have shown that the muscarinic agonist pilocarpine (Salamone
et al., 2012) and the anticholinesterase galantamine (Podurgiel et al., in prep; see
Appendix 1) can induce TJMs in mice in a dose dependent manner. As is seen with rats,
MSX-3 is capable of attenuating TJMs induced by these cholinomimetics (Salamone et
al. 2012; Podurgiel et al., in prep). Additionally, adenosine A2A receptor knockout (KO)
mice show significantly fewer pilocarpine-induced TJMs compared to wild-type (wt)
controls. This same pattern of behavior is seen with administration of tetrabenazine. TBZ
administration in mice induces TJMs in a dose-dependent manner and A2A KO mice show
significantly less TBZ-induced TJMs compared to wild-type mice (López-Cruz et al., in
prep, see appendix 3). Results from experiment 4 are therefore consistent with these
previous studies with mice, but extend them by showing that pharmacological depletion
of DA can induce TJMs in mice, and that pharmacological antagonism of the A2A
receptor is capable of attenuating TBZ-induced TJMs in mice.
In order to provide a cellular marker of the ability of MSX-3 to attenuate the
cellular actions of TBZ, we used c-Fos immunoreactivity. The results of experiment 5
demonstrated that a behaviorally active dose of MSX-3 was able to reduce TBZ-induced
increases in c-Fos expression. c-Fos provides a cellular marker related to signal
transduction processes (Segovia et al., 2012), and previous research has shown that DA
D2 receptor antagonism induces c-Fos expression in striatal areas (Pinna et al., 1999;
Betz et al., 2009; Farrar et al., 2010; Santerre et al., 2012). Similarly, earlier work by
Pollack and Angerer (2005) showed an increase in Fos-like immunoreactivity in the rat
striatum after administration of reserpine. Systemic injections of A2A antagonists have
been shown to attenuate striatal c-Fos expression induced by DA antagonists, including
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haloperidol and pimozide (Pinna et al., 1999; Betz et al., 2009; Farrar et al., 2010;
Santerre et al., 2012). In experiment 5, MSX-3 reversed TBZ-induced c-Fos expression in
a neostriatal subregion known as the VLS. The VLS was chosen as the region of interest
because this is the neostriatal region most closely related to the production of TJMs
induced by DA depletions (Jicha and Salamone, 1991; Finn et al., 1998) and
cholinomimetics (Salamone et al., 1990; Cousins et al., 1998). Furthermore, Salamone et
al. (2008) demonstrated that pimozide induced TJMs could be attenuated by local
injections of MSX-3 into the VLS. These data are consistent with previous research by
Betz et al. (2009) who showed that the A2A antagonist KW 6002 attenuated pimozideinduced c-Fos expression in the VLS. The results from experiment 5 therefore suggest
that MSX-3 attenuated TBZ-induced TJMs because it blunted the basic cellular effects
caused by a reduction in DA transmission at D2 receptors. Since A2A and D2 receptors
are colocalized, and MSX-3 was capable of attenuating the increase in c-Fos positive
cells induced by TBZ, this cellular interaction is likely to be taking place in the same set
of neurons. Therefore, even though TBZ reduces DA transmission in both the
striatonigral and striatopallidal pathway by reducing stimulation of D1 and D2 receptors
respectively, our data suggests that the increase in c-Fos expression is due to actions on
striatopallidal pathway neurons. This conclusion is in accordance with previous research
showing that D2 receptor blockade consistently induces c-Fos expression (a marker of cAMP-related signal transduction pathways) in the neostriatum (Dragunow et al., 1990;
MacGibbon et al., 1994; Pinna et al., 1997, 1999; Atkins et al., 1999; Young et al. 1999;
Betz et al., 2009; Farrar et al., 2010; Santerre et al., 2012), and that D2 and A2A receptors
are co-localized on enkephalin-positive “indirect pathway” striatopallidal medium spiny
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neurons and converge on the same signal transduction mechanisms (Ferre et al., 2001,
2008).
Currently in our laboratory, we use the DA depleting agent reserpine and the DA
antagonists haloperidol and pimozide as DA-related models for the induction of TJMs
(Salamone et al., 2008; Betz et al., 2009; Collins et al., 2012). Yet despite the utility of
these drugs, our results indicate that TBZ has several advantages over reserpine,
pimozide or haloperidol as a method for inducing TJM activity. As previously discussed,
reserpine has a similar mechanism of action as TBZ (blockade of vesicular storage
through VMAT inhibition), and thus can be used as a DA depleting agent for the
induction of TJMs (Steinpreis and Salamone, 1993; Salamone et al., 2008). Nevertheless,
there also are some differences between these two drugs; reserpine is nonselective for
VMAT1 and VMAT2, and in contrast to TBZ, reserpine is irreversible. When used in the
TJM model, reserpine-induced motor impairments were shown to sensitize over repeated
injections (unpublished observations). This meant that in a repeated measures design
with multiple injections, reserpine-treated animals eventually developed severe akinesia
and catalepsy, as well sedation, and these effects interfered with the ability to display
TJMs (unpublished observations). In contrast, our results showed a consistent response
with TBZ throughout the course of the experiments, and we never recorded the
emergence of these gross impairments after repeated weekly injections of TBZ.
Furthermore, although haloperidol and pimozide can induce TJMs after acute injection,
we have found that a robust jaw movement response with haloperidol and pimozide
requires subchronic administration to prime the behavioral response. In these models,
TJMs are typically observed on day 14 of haloperidol treatment and on day 7 of pimozide
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treatment (e.g. Salamone et al., 2008; Betz et al., 2009; Collins et al., 2012). In contrast,
TBZ administration induced consistent TJMs after acute administration. For all these
reasons, TBZ appears to be a more useful tool for the induction of TJM activity than
many other substances that have previously been employed.
TBZ is also currently being employed in behavioral paradigms that evaluate
effort-related choice processes. Nunes et al. (in prep) have found that systemic
administration of lower doses of TBZ (i.e., 0.75 mg/kg-1.0 mg/kg) alter effort-related
decision making as measured by the concurrent fixed ratio (FR 5)/chow feeding choice
task. Furthermore, Yohn et al. (in prep) demonstrated that 0.75 mg/kg TBZ altered arm
selection in a T-maze barrier choice task, which also provides a measure of effort related
choice behavior. In both instances, administration of TBZ decreased selection of a high
cost/high reinforcement option, and increased selection of a low cost/low reinforcement
option. Furthermore, in both cases, coadministration of MSX-3 (0.5, 1.0, 2.0 mg/kg) was
able to attenuate these shifts in effort-related choice behavior. Additionally,
administration of 0.75 mg/kg TBZ induces an increase in c-Fos and pDARPP-32(Thr34)
expression in the nucleus accumbens core, a critical area for D2/A2A interactions
regulating effort-related choice behavior (Nunes et al., in prep). These results are
consistent with the behavioral data presented in experiments 1-4, as well as the
immunocytochemisty presented in experiment 5. Although TJMs are related to neostriatal
function, and represent an animal model of Parkinsonian tremor, tests of effort-based
choice behavior are thought to be useful as animal models of the effort-related
motivational symptoms of depression. Thus, recent animal work with TBZ indicates that
two of the major side effects of this drug in humans, depression-related symptoms and
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Parkinsonism, can be studied in rodent models, provided that the right doses and
behavioral tasks are used.
Future research should continue to develop and characterize the TBZ model of
Parkinsonian resting tremor. As previously discussed, EMG recordings from the
temporalis muscle should be obtained to further characterize the local frequency of TJMs
and pattern of muscle activity induced by TBZ. Additionally, future studies should study
the induction of DARPP-32 immunoreactivity. DARPP-32 is another useful marker of
DA-related signal transduction activity (Segovia et al., 2012). Therefore, future research
should assess the expression of phosphorylated DARPP32 at the threonine 34 site
(pDARPP32 Thr34), and phosphorylated DARPP32 at the threonine 75 site (pDARPP32
Thr75), in the VLS after administration of TBZ. The histological technique of double
labeling immunofluorescence should be used in order to determine which subset of
neurons preferentially express pDARPP32 Thr34 and pDARPP32 Thr75 after systemic
injection of TBZ. Using this technique, researchers will be able to visualize two antigens
(e.g. DARPP32 and Enkephalin) in the same neuron. Based upon previous studies of
DARPP-32 phosphorylation (Bateup et al., 2008), TBZ administration should increase
pDARPP32 Thr75 expression in substance-P containing neurons, and pDARPP32 Thr34
expression should occur mainly in enkephalin-positive neurons. Future research could
also employ this animal model of Parkinsonian resting tremor as a platform for
evaluating possible antiparkinsonian agents. Using this animal model of Parkinsonian
tremor, our results from experiments 3 and 4 suggest that adenosine A2A antagonists may
alleviate the Parkinsonian side effects seen in HD patients taking TBZ for treatment of
chorea.
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Figures:

Figure 1: The VMAT2 inhibitor tetrabenazine (2.0 mg/kg) significantly induces
tremulous jaw movements compared to vehicle control. * = p < .05
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Figure 2: The vast majority (92%) of the tremulous jaw movements induced by 2.0
mg/kg tetrabenazine takes place in the 3.0-7.5 Hz frequency range, with a peak from 4.06.0 Hz. The number of inter-movement intervals showed an overall significant difference
across the different interval bins (F(29,174) = 14.464, p<.0001)
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Figure 3: 2.0 mg/kg tetrabenazine significantly induces tremulous jaw movements
compared to vehicle control in rats, # = p < .05. The adenosine A2A antagonist MSX-3
attenuates tremulous jaw movements induced by 2.0 mg/kg tetrabenazine in rats, * = p <
.05.
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Figure 4: 10.0 mg/kg tetrabenazine significantly induces tremulous jaw movements
compared to vehicle control in mice, # = p < .05. The adenosine A2A antagonist MSX-3
attenuates tremulous jaw movements induced by 10.0 mg/kg tetrabenazine in mice, * = p
< .05.
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Figure 5: 2.0 mg/kg tetrabenazine significantly increases c-Fos expression in the VLS
compared to vehicle control. # = p < .05 The adenosine A2A antagonist MSX-3 attenuates
c-Fos expression in the VLS induced by 2.0 mg/kg tetravenazine * = p < .05. Panel A:
V/V; Panel B: TBZ/V; Panel C: TBZ/MSX-3
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Appendix:

Appendix 1: The anticholinesterase galantamine induces tremulous jaw movements in
mice.
* = p < .05

59

Appendix 2: 2.5 mg/kg tetrabenazine significantly induces tremulous jaw movements
compared to vehicle control in mice, # = p < .05. The adenosine A2A antagonist MSX-3
attenuates tremulous jaw movements induced by 2.5 mg/kg galantamine in mice, * = p <
.05
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Appendix 3: Tetrabenazine induces tremulous jaw movements in wild type (WT) mice.
A2A KO mice show significantly less tetrabenazine-induced tremulous jaw movements
than WT mice in response to 5.0 and 10.0 mg/kg tetrabenazine.
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